To address this caveat, recent research endeavors have focused on generating STING-activating compounds that are amenable to systemic delivery or STING-activating nanoparticles designed to efficiently deliver the endogenous STING ligand into the cytosol.102 Such an approach has been explored in preclinical models of neuroblastoma that led to inhibition of tumour growth and improved response to ICB.102 However, the utility of STING activating compounds against neuroblastoma remains to be explored in clinical trials. Here, STING1 is linked to neoplasm.